Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Urinary Bladder Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 9Neoplasms 8Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 6Neoplasm Metastasis 6Lung Neoplasms 6Colorectal Neoplasms 5Ovarian Neoplasms 4Lymphoma, Follicular 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Cholangiocarcinoma 3Brain Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 1omega-N-Methylarginine 1dehydroftorafur 1atezolizumab 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × DNA Repair-Deficiency Disorders × atezolizumab × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡